2024-05-15 06:32 | UU:NNVC | | News Release200 | NanoViricides Has Filed its Quarterly Report |
2024-05-14 06:33 | UU:NNVC | | News Release200 | A Novel Broad-Spectrum Antiviral with Activity Against RSV |
2024-05-10 06:32 | UU:NNVC | | News Release200 | NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City |
2024-05-08 06:32 | UU:NNVC | | News Release200 | A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox |
2024-05-06 06:31 | UU:NNVC | | News Release200 | A Novel Broad-Spectrum Antiviral with Activity Against Influenza A |
2024-04-30 06:33 | UU:NNVC | | News Release200 | NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon |
2024-02-15 06:31 | UU:NNVC | | News Release200 | NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon |
2024-02-01 06:22 | UU:NNVC | | News Release200 | Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics |
2024-01-29 06:31 | UU:NNVC | | News Release200 | Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found |
2024-01-04 06:31 | UU:NNVC | | News Release200 | NanoViricides to Present at the Biotech Showcase in San Fransisco |
2023-11-29 13:33 | UU:NNVC | | News Release200 | NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 |
2023-11-28 06:42 | UU:NNVC | | News Release200 | The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company ¢ € ™s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides |
2023-11-15 06:47 | UU:NNVC | | News Release200 | NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications |
2023-11-14 06:46 | UU:NNVC | | News Release200 | Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development |
2023-10-16 06:47 | UU:NNVC | | News Release200 | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV |
2023-10-12 06:46 | UU:NNVC | | News Release200 | NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET |
2023-09-27 08:46 | UU:NNVC | | News Release200 | Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant |
2023-08-31 08:01 | UU:NNVC | | News Release200 | NanoViricides progressing well with new Covid study |
2023-08-21 06:45 | UU:NNVC | | News Release200 | The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company ¢ € ™s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides |
2023-07-19 09:16 | UU:NNVC | | News Release200 | SARS-CoV-2 Is Not Done Yet ƒ ¢ ‚ € ‚ ” Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? |
2023-07-13 08:33 | UU:NNVC | | News Release200 | NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst |
2023-07-11 09:26 | UU:NNVC | | News Release200 | Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials ƒ ¢ ‚ € ‚ “ What Other Viruses Could This COVID Treatment Target? |
2023-07-11 06:46 | UU:NNVC | | News Release200 | Company ¢ € ™s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides |
2023-07-06 09:02 | UU:NNVC | | News Release200 | NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment |
2023-07-06 06:45 | UU:NNVC | | News Release200 | Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs |
2023-06-29 15:01 | UU:NNVC | | News Release200 | NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2 |
2023-06-29 06:45 | UU:NNVC | | News Release200 | NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
2023-05-31 06:40 | UU:NNVC | | News Release200 | NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET |